von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction

被引:2
作者
Warlo, Ellen M. K. [1 ,2 ,6 ]
Kalstad, Are A. [1 ]
Myhre, Peder L. [2 ,3 ]
Solheim, Svein [1 ]
Arnesen, Harald [1 ,2 ]
Tveit, Arnljot [2 ,4 ]
Holme, Pal Andre [2 ,5 ]
Seljeflot, Ingebjorg [1 ,2 ]
Bratseth, Vibeke [1 ]
机构
[1] Oslo Univ Hosp, Ctr Clin Heart Res, Dept Cardiol, Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
[3] Akershus Univ Hosp, Dept Cardiol, Lorenskog, Norway
[4] Vestre Viken Hosp Trust, Baerum Hosp, Dept Med Res, Gjettum, Norway
[5] Oslo Univ Hosp, Dept Haematol, Oslo, Norway
[6] Oslo Univ Hosp, Ctr Clin Heart Res, Dept Cardiol, Pb 4956 Nydalen, N-0424 Oslo, Norway
关键词
ADAMTS-13; aged; atrial fibrillation; cardiovascular diseases; thrombospondin; 1; von Willebrand factor; CLEAVING PROTEASE ADAMTS13; CORONARY-HEART-DISEASE; ATRIAL-FIBRILLATION; ENDOTHELIAL DYSFUNCTION; PREDICTIVE-VALUE; PROGNOSTIC VALUE; PLASMA; RISK; BIOMARKERS; MORTALITY;
D O I
10.1016/j.rpth.2023.100164
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF's cleavage site, protecting it from degradation. Low ADAMTS-13 and high VWF have been associated with cardiovascular disease and atrial fibrillation (AF).Objectives: We aimed to investigate whether VWF, ADAMTS-13, and TSP-1 are associated with clinical outcome.Methods: Elderly patients with a recent myocardial infarction (MI) (n = 1027) were followed for 2 years. Blood was collected 2 to 8 weeks after the MI for ADAMTS-13, VWF, and TSP-1 measures. The primary endpoints (major adverse cardiovascular events; n = 210) included the first event of MI, stroke, heart failure hospitalization, coronary revascularization, and all-cause death. Total mortality was also registered (n = 56). The secondary endpoint was new-onset AF (n = 43).Results: Concentrations of VWF, ADAMTS-13, and TSP-1 did not intercorrelate. The risk of major adverse cardiovascular events was altered in patients with VWF > median (hazard ratio [HR], 1.4; 95% CI, 1.0-1.8; P = .03) and ADAMTS-13 > median (HR, 0.7; 95% CI, 0.5-0.9; P = .02); however, it was not significant in adjusted models. VWF and ADAMTS-13 were significantly associated with total mortality, with a HR of 2.7 (95% CI, 1.6-4.6; P < .001) for VWF (Q4 vs. Q1-Q3) and HR of 0.3 (95% CI, 0.2-0.5; P < .001) for ADAMTS-13 (Q2-4 vs. Q1). The associations persisted in multivariable analysis, but the significance disappeared for VWF after correcting for high-sensitivity C-reactive protein. The risk of new-onset AF was lower in patients with VWF > median (HR, 0.5; 95% CI, 0.3-1.0; P = .04]), and this was still significant after adjustments.Conclusion: Although low ADAMTS-13 predicted death, the cardiovascular risk associated with VWF and ADAMTS-13 was weaker than previously reported. Low VWF is associated with new-onset AF and needs further research.
引用
收藏
页数:12
相关论文
共 41 条
[1]   Update on ADAMTS13 and VWF in cardiovascular and hematological disorders [J].
Akyol, Omer ;
Akyol, Sumeyya ;
Chen, Chu-Huang .
CLINICA CHIMICA ACTA, 2016, 463 :109-118
[2]   Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity [J].
Al-Awadhi, Anwar ;
Adekile, Adekunle ;
Marouf, Rajaa .
ACTA HAEMATOLOGICA, 2021, 144 (02) :182-189
[3]   Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study [J].
Alonso, Alvaro ;
Tang, Weihong ;
Agarwal, Sunil K. ;
Soliman, Elsayed Z. ;
Chamberlain, Alanna M. ;
Folsom, Aaron R. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 155 (02) :217-222
[4]   Increased plasma cathepsin S and trombospondin-1 in patients with acute ST-segment elevation myocardial infarction [J].
Befekadu, Rahel ;
Christiansen, Kjeld ;
Larsson, Anders ;
Grenegard, Magnus .
CARDIOLOGY JOURNAL, 2019, 26 (04) :385-393
[5]   Inflammation, von Willebrand factor, and ADAMTS13 [J].
Chen, Junmei ;
Chung, Dominic W. .
BLOOD, 2018, 132 (02) :141-147
[6]   Atrial fibrillation and the prothrombotic state in the elderly - The Rotterdam Study [J].
Conway, DSG ;
Heeringa, J ;
Van Der Kuip, DAM ;
Chin, BSP ;
Hofman, A ;
Witteman, JCM ;
Lip, GYH .
STROKE, 2003, 34 (02) :413-417
[7]   Atrial Fibrillation and Endothelial Dysfunction: A Potential Link? [J].
Corban, Michel T. ;
Toya, Takumi ;
Ahmad, Ali ;
Lerman, Lilach O. ;
Lee, Hon-Chi ;
Lerman, Amir .
MAYO CLINIC PROCEEDINGS, 2021, 96 (06) :1609-1621
[8]   Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura [J].
Franchini, Massimo ;
Mannucci, Pier Mannuccio .
BLOOD TRANSFUSION, 2008, 6 (03) :127-135
[9]   Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation [J].
Freynhofer, Matthias K. ;
Gruber, Susanne C. ;
Bruno, Veronika ;
Hoechtl, Thomas ;
Farhan, Serdar ;
Zaller, Vera ;
Wojta, Johann ;
Huber, Kurt .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (01) :317-325
[10]   Predictive value of thrombospondin-1 for outcomes in patients with acute ischemic stroke [J].
Gao, Jian-Bo ;
Tang, Wei-Dong ;
Wang, Hong-Xiang ;
Xu, Yan .
CLINICA CHIMICA ACTA, 2015, 450 :176-180